The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a more substantial reduction in body size and enhance metabolic function, particu